MigraineCut Spray

This product is the result of 25 years of international researches that consists of various herbs extract such as lavender, Violet, Fennel, Coriander and Marjoram which the anti- Migraine effect of these herbs have been mentioned in Iranian traditional medicine. In addition to the positive and treatment effects for Migraine headaches, this product helps reduce the severity of other sorts of headaches. The benefits of this product include a wide range of drug absorption, painless, convenient and safe use, high and rapid absorption by the brain and the central nervous system. Changes in the diameter of the vessels of the head, the secretion of melatonin and, consequently, the adjustment of sleep and biological rhythms, decrease the amount of free nitric oxide, are the potentially powerful mechanism of actions of this product. More than 300 patients with Migraine were studied in a clinical trial which used this spray. About 96% of patients claimed that they have been able to control their headaches. Also, About 81% of patients have been treated definitively and patients acknowledged the removal of their Migraine headaches.

22.00 20.20
Availability: In stock
Email to a Friend:

Reviews (1)

1 review for MigraineCut Spray

  1. lino


Add a review

Your email address will not be published. Required fields are marked *


Migraine headache

Dosage form and packaging

Nasal Spray 20 ml


* Lavender (Lavandula angustifolia)
* Melilot (Melilotus officinalis)
* Sweet Violet (Viola odorata)
* Fennel (Foeniculum vulgare miller)
* Coriander (Corianderum sativum)
* Marjoram (Origanum majorana)

Effective Ingredients

Cineol, eucalyptol, alpha-ionone, anethole, linalool, and carvacrol

Suggested Use

The highest amount of MigraineCut® that is used to for CURATIVE treatment course is one puff in each nostril every three hours from 9 a.m. to 12 a.m. The minimum daily amount is three puffs in each nostril. The intervals, including 4, 6 or 8 hours between the two puffs, are determined by the counselors or specialists, according to the state of the headaches or the clinical conditions of the patients.
In addition, MigraineCut® is also taken during a migraine attack. Such usage should not interfere with the regular treatment time-table, e.g., if the MigraineCut® is to be taken at 3 p.m. based on the prescription time-table and an attack occurs at 2 p.m. and the medicine is taken as a preventive base, then the patient has to take the medicine at 3 p.m. too to comply with the regular time-table.
If the MigraineCut® is taken based on the instructions in the medicine brochure, each bottle of the spray lasts for about 10 days. This duration can be extended to 25 days in case other permitted timings are applied. The desired migraine treatment duration, as concluded from the clinical trials, has been about four months, meaning that at least six bottles of spray are recommended to the patients.


Migraine patients with episodic and chronic headaches have shown a significant decrease in their severity and clinical symptoms indices after using MigraineCut®. The patients suffering from “medication overuse headache” (MOH) also benefitted from MigraineCut®, but usually throughout a longer period of time with similar or even better results of treatment.
Patients with migraine accompanied by cluster and tension headaches also had their migraines decreased by using MigraineCut®. But the reduction of other types of headaches requires special treatments and counseling by neurologists. Aramesh Tehran Multidisciplinary Pain Clinic has opened a free call center to help patients to manage their headaches over the telephone.
MigraineCut® has proven effective in curing and reduction of various kinds of migraine in different people with different reasons. In fact, the change in the diameter of the blood vessels in the head (the brain) for managing headaches, enhancing melatonin secretion to improve sleep quality and biological rhythms and decreasing the free nitric acid in the blood are among the powerful action mechanisms of the medicine.
MigraineCut® was based on the guidelines, instructions, and indices of the International Headache Society (IHS). More than 300 patients participated in the clinical trial. About 81% of the migraine patients reported full termination of their headaches. Another 15% of people felt a significant positive change in at least one of the indices of headache (i.e. frequency, duration, and intensity), and also remarkable improvement in their clinical symptoms such as auras. These patients claim that they have been able to manage their headaches after treatment by MigraineCut®. As indicated in Figure 1, the average severity of the migraine patients treated by MigraineCut® has dropped from 1400 units to 303 in the first month and to 151 within a period of 4 months, i.e. 88.6% reduction in the severity of migraine headache of the patients.


Using MigraineCut® while taking anticoagulants or trinitroglycerin is not recommended. In addition, children under the age of two and pregnant women are prohibited from using the medicine.

Adverse Effects

There has been no account of any harmful effects resulting from the usage of MigraineCut® on the patients of epilepsy, cardiovascular or special/rare diseases. By taking MigraineCut®, mild dryness of the nostrils in about 15% of the patients with sensitive nasal mucous or with a history of nose bleeding may occur. This can easily be overcome by applying olive or sesame oil to the nostrils in between the puffs of MigraineCut®.



After many years of rigorous research and large clinical trials at the only migraine clinic in the Middle East (Aramesh Multidisciplinary Pain Clinic of Tehran), MIM Daroo® Pharmaceutical Company introduced the CURATIVE MEDICINE FOR MIGRAINE HEADACHES in 2009. The first newly developed drug was in the form of inhalation and needed special processes to be used only at the clinics. The first curative migraine medicine was not user-friendly and patients would face difficulties while it incurred the heavy costs of clinical treatment. The R&D team of MIM Daroo® was encouraged to develop a new version of migraine CURATIVE medicine.
In 2016, MigraineCut®, the first spray to CURE MIGRAINE passed all the requirements and was registered in the Food and Drug Administration (FDA) of Iran and received mass industrial production license. The clinical trials were performed based on the International Headache Society (IHS) guidelines on 300 patients. The CURATIVE EFFICACY of MigraineCut® has been 81% definite cure (as stated in the long-term follow-up surveys after the treatment) with nearly 96% mitigation.

Advantages of the nasal spray:
Delivering medicine through the nose has the following advantages:
• Vast absorption area (the rich blood vessels network) = approximately 160 cm2
• A vast network available to medicine particles due to their microscopic size
• Easy to use by patients
• Good access to the lymphatic system
• Quick absorption in the blood (Bioavailability: BA= 60-70%); this is just second in rank comparing to intravenous injection (BA=100%) with a significant difference from the oral pathway (BA=5-10%), thus resulting in:
1. Not being affected by the digestive system in any way
2. The high permeability of medicine components especially for lipophilic compounds with a low molecular weight
3. Not being metabolized by the liver in its first phase of delivery.
* Store at room temperature (0-30ºC).
* Protect from direct light and heat.
* Keep out of the reach of children.